Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To compare the additive efficacy of GS-6624 vs. placebo in combination with FOLFIRI as measured by improvement in progression free survival (PFS) in subjects with metastatic KRAS mutant colorectal adenocarcinoma who have progressed following a first line oxaliplatin- and fluoropyrimidine-containing regimen.
Critère d'inclusion
- Metastatic KRAS Mutant Colorectal Adenocarcinoma